A dose escalation and proof-of-concept clinical trial of avapritinib in patients with indolent and smoldering systemic mastocytosis (SM)

Trial Profile

A dose escalation and proof-of-concept clinical trial of avapritinib in patients with indolent and smoldering systemic mastocytosis (SM)

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Systemic mastocytosis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2017 New trial record
    • 10 Dec 2017 According to a Blueprint Medicines media release, the company plans to initiate this trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top